Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home / News / 2012 News / Discovery Suggests New Combination Therapy Strategy for Basal-Like Breast Cancers

Discovery Suggests New Combination Therapy Strategy for Basal-Like Breast Cancers

by Susan Lucas last modified May 23, 2012 09:50 AM
Chapel Hill, NC – Multiple research projects – including a 2006 study conducted at the University of North Carolina at Chapel Hill – have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple negative breast cancer, is more prevalent in African Americans than their Caucasian counterparts.
Discovery Suggests New Combination Therapy Strategy for Basal-Like Breast Cancers

This research is featured on the cover of the May 2012 issue of Cancer Cell.

A new study led by UNC Lineberger scientist Charles Perou, PhD, and Sean Egan, PhD, from The Hospital for Sick Children in Toronto, Ontario, demonstrates that deletion of a sugar transferase called LFNG (nicknamed “lunatic fringe”), promotes cell proliferation and tumor formation of basal-like breast cancers. 

In a laboratory model, the deletion of LFNG not only caused tumors to form but also activated two cellular signaling pathways thought to be important in tumor formation.  The team found increased activation of both notch signaling (a receptor found on the surface of cells that is involved in stem cell differentiation and development) and increased expression of the Met oncogene. 

Taking the laboratory model a step further, the team examined these same genes and signaling pathways in basal-like tumors and found the same genetic signature.

“This is exciting because there are drugs in development that target each of these pathways.  While targeting each pathway alone might work, our findings suggest that combination therapy could be a promising strategy for treating these basal-like tumors,” says Dr. Perou, who is the May Goldman Shaw Distinguished Professor of Molecular Oncology and professor of genetics, and pathology & laboratory medicine at the UNC School of Medicine.

Basal-like breast cancer tends to be more aggressive and have a poorer prognosis than other types, making up about 15 percent of all breast cancers.  In young African-American women who develop breast cancer, the subtype makes up about 39 percent of all diagnoses.  It is primarily treated with chemotherapy, although newer targeted drugs are being tested in clinical trials.

In addition to Dr. Perou, other UNC scientists involved included Jerry Usary, Aleix Prat, and Wei Zhou. Members of Dr. Egan’s group included scientists from a number of institutions affiliated with the University of Toronto, the Center for Comparative Medicine at the University of California, Davis, and the Jackson Laboratory in Bar Harbor, Maine.

The research was supported by the Canadian Cancer Society Research Institute, Susan G. Komen for the Cure, Genome Canada, the NCI Breast SPORE Program, and the Breast Cancer Research Foundation.